

=> D HIS L17

(FILE 'HCAPLUS' ENTERED AT 10:31:22 ON 03 JUN 1999)
L17 1 S 125:293042/DN

=> SELECT RN L17

ENTER ANSWER NUMBER OR RANGE (1-):1

E66 THROUGH E111 ASSIGNED

=> FIL REG

FILE 'REGISTRY' ENTERED AT 10:33:04 ON 03 JUN 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1999 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 28 MAY 99 HIGHEST RN 223764-44-1
DICTIONARY FILE UPDATES: 03 JUN 99 HIGHEST RN 223764-44-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 13, 1999

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

=> S E66-111

1 10540-29-1/BI
(10540-29-1/RN)
1 110590-61-9/BI
(110590-61-9/RN)
1 11128-99-7/BI
(11128-99-7/RN)
1 113-92-8/BI
(113-92-8/RN)
1 114798-26-4/BI
(114798-26-4/RN)
1 120-80-9/BI
(120-80-9/RN)
1 126509-46-4/BI
(126509-46-4/RN)
1 12772-57-5/BI
(12772-57-5/RN)
1 129912-34-1/BI
(129912-34-1/RN)
1 135911-02-3/BI
(135911-02-3/RN)
1 1398-62-5/BI
(1398-62-5/RN)
1 15826-37-6/BI
(15826-37-6/RN)
1 182930-58-1/BI
(182930-58-1/RN)
1 1845-11-0/BI
(1845-11-0/RN)

Searched by John Dantzman 308-4488

1 18550-55-5/BI
(18550-55-5/RN)
1 21829-25-4/BI
(21829-25-4/RN)
1 23110-15-8/BI
(23110-15-8/RN)
1 23593-75-1/BI
(23593-75-1/RN)
1 24280-93-1/BI
(24280-93-1/RN)
1 25614-03-3/BI
(25614-03-3/RN)
1 3316-09-4/BI
(3316-09-4/RN)
1 33507-63-0/BI
(33507-63-0/RN)
1 37270-94-3/BI
(37270-94-3/RN)
1 38096-31-0/BI
(38096-31-0/RN)
1 4431-00-9/BI
(4431-00-9/RN)
1 4733-39-5/BI
(4733-39-5/RN)
1 50679-08-8/BI
(50679-08-8/RN)
1 51-45-6/BI
(51-45-6/RN)
1 51481-61-9/BI
(51481-61-9/RN)
1 52698-84-7/BI
(52698-84-7/RN)
1 57381-26-7/BI
(57381-26-7/RN)
1 65154-06-5/BI
(65154-06-5/RN)
1 65899-73-2/BI
(65899-73-2/RN)
1 67-43-6/BI
(67-43-6/RN)
1 70050-43-0/BI
(70050-43-0/RN)
1 7491-74-9/BI
(7491-74-9/RN)
1 75847-73-3/BI
(75847-73-3/RN)
1 76547-98-3/BI
(76547-98-3/RN)
1 83-89-6/BI
(83-89-6/RN)
1 84088-42-6/BI
(84088-42-6/RN)
1 9015-82-1/BI
(9015-82-1/RN)
1 9023-09-0/BI
(9023-09-0/RN)
1 9024-61-7/BI

(9024-61-7/RN)
1 9039-06-9/BI
(9039-06-9/RN)
1 9055-65-6/BI
(9055-65-6/RN)
1 91-81-6/BI
(91-81-6/RN)
L18 46 (10540-29-1/BI OR 110590-61-9/BI OR 11128-99-7/BI OR
113-92-8/BI OR 114798-26-4/BI OR 120-80-9/BI OR 126509-46-4/BI OR
12772-57- 5/BI OR 129912-34-1/BI OR 135911-02-3/BI OR 1398-62-5/BI OR
15826-37-6/BI OR 182930-58-1/BI OR 1845-11-0/BI OR
18550-55-5/BI OR 21829-25-4/BI OR 23110-15-8/BI OR 23593-75-1/BI OR
24280-93- 1/BI OR 25614-03-3/BI OR 3316-09-4/BI OR 33507-63-0/BI OR
37270- 94-3/BI OR 38096-31-0/BI OR 4431-00-9/BI OR 4733-39-5/BI OR
50679-08-8/BI OR 51-45-6/BI OR 51481-61-9/BI OR 52698-84-7/BI
OR 57381-26-7/BI OR 65154-06-5/BI OR 65899-73-2/BI OR
67-43-6/BI OR 70050-43-0/BI OR 7491-74-9/BI OR 75847-73-3/BI OR
76547-98-3 /BI OR 83-89-6/BI OR 84088-42-6/BI OR 9015-82-1/BI OR
9023-09-0/ BI OR 9024-61-7/BI OR 9039-06-9/BI OR 9055-65-6/BI OR
91-81-6/BI)

=> D BIB ABS HITSTR

L19 ANSWER 1 OF 1 HCPLUS COPYRIGHT 1999 ACS
 AN 1996:660913 HCPLUS
 DN 125:293042
 TI Use of angiogenesis suppressors for inhibiting hair growth
 IN Ahluwalia, Gurpreet S.; Styczynski, Peter; Shander, Douglas
 PA Handelman, Joseph H., USA
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626712	A2	19960906	WO 96-US2790	19960227
	WO 9626712	A3	19961121		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	CA 2213404	AA	19960906	CA 96-2213404	19960227
	AU 9653009	A1	19960918	AU 96-53009	19960227
	EP 812185	A2	19971217	EP 96-909552	19960227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	BR 9607060	A	19981215	BR 96-7060	19960227
	JP 11501035	T2	19990126	JP 96-526415	19960227
PRAI	US 95-396446		19950228		
	WO 96-US2790		19960227		
AB	A method of inhibiting hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatol. acceptable compn. contg. a non-steroidal suppressor of angiogenesis. The effective compds. include sulfotransferase inhibitors, heparin binding antagonists, Cu chelators, histidine decarboxylase inhibitors, mast cell degranulation inhibitors, histamine receptor antagonists, ACE inhibitors, angiotensin II receptor antagonists, prostaglandin synthetase inhibitors, NK1 receptor antagonists, PAF receptor antagonists, and cytochrome P 450 reductase inhibitors. A topical prepn. contg. 10 % bathocuproine, was applied to male intact Golden Syrian hamsters; hair growth was inhibited by 81 %.				
IT	67-43-6, Diethylenetriamine pentaacetic acid 83-89-6, Quinacrine 91-81-6, Tripelennamine 113-92-8 120-80-9, 1,2-Benzenediol, biological studies 1398-62-5, Chitin sulfate 1845-11-0, Nafoxidine 3316-09-4, p-Nitrocatechol 4431-00-9, Aurintricarboxylic acid 4733-39-5, Bathocuproine 7491-74-9, Piracetam 10540-29-1, Tamoxifen 12772-57-5, Radicicol 15826-37-6, Cromoglycate 18550-55-5, Hyponitric acid 21829-25-4, Nifedipine 23110-15-8, Fumagillin 23593-75-1, Clotrimazole 24280-93-1, Mycophenolic acid 25614-03-3, Bromocryptine 37270-94-3, Platelet factor-4 38096-31-0D, Diaminoanthraquinone, derivs. 50679-08-8, Terfenadine 51481-61-9, Cimetidine 52698-84-7, Bathocuproinesulfonate 57381-26-7, Irsogladine				


Searched by John Dantzman 308-4488

65899-73-2, Tioconazole 70050-43-0, .alpha.-
 Fluoromethylhistidine 75847-73-3, Enalapril 76547-98-3
 , Lisinopril 84088-42-6, Linomide 110590-61-9
 114798-26-4, Losartan 126509-46-4, Eponemycin
 129912-34-1 135911-02-3 182930-58-1
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)

(angiogenesis suppressors for inhibiting hair growth)


RN 67-43-6 HCPLUS

CN Glycine, N,N-bis[2-[bis(carboxymethyl)amino]ethyl]- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 83-89-6 HCPLUS

CN 1,4-Pantanediamine, N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 91-81-6 HCPLUS

CN 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 113-92-8 HCPLUS

CN 2-Pyridinepropanamine, .gamma.- (4-chlorophenyl)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132-22-9


CMF C16 H19 Cl N2




CM 2

CRN 110-16-7
 CMF C₉ H₁₁ Cl N
 CDES 2:Z

Double bond geometry as shown.




RN 120-80-9 HCPLUS
 CN 1,2-Benzenediol (9CI) (CA INDEX NAME)



RN 1398-62-5 HCPLUS
 CN Chitin, hydrogen sulfate (ester) (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9
 CMF H₂ O₄ S




CM 2

CRN 1398-61-4
 CMF Unspecified
 CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 1845-11-0 HCPLUS

CN Pyrrolidine, 1-[2-[4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 3316-09-4 HCPLUS

CN 1,2-Benzenediol, 4-nitro- (9CI) (CA INDEX NAME)




RN 4431-00-9 HCPLUS

CN Benzoic acid, 5-[(3-carboxy-4-hydroxyphenyl)(3-carboxy-4-oxo-2,5-cyclohexadien-1-ylidene)methyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 4733-39-5 HCAPLUS

CN 1,10-Phenanthroline, 2,9-dimethyl-4,7-diphenyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 7491-74-9 HCAPLUS

CN 1-Pyrrolidineacetamide, 2-oxo- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 10540-29-1 HCAPLUS

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)


(CA INDEX NAME)

Double bond geometry as shown.





RN 12772-57-5 HCAPLUS


CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione,
8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-,
(1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)




RN 15826-37-6 HCAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 5,5'-(2-hydroxy-1,3-propanediyl)bis(oxy)bis[4-oxo-, disodium salt (9CI) (CA INDEX NAME)



RN 18550-55-5 HCAPLUS
CN Hyponitric acid (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 21829-25-4 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dimethyl ester (9CI) (CA INDEX NAME)




RN 23110-15-8 HCPLUS

CN 2,4,6,8-Decatetraenedioic acid,
mono[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-
methyl-3-(3-methyl-2-butene-1-yl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester,
(2E,4E,6E,8E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 23593-75-1 HCPLUS


CN 1H-Imidazole, 1-[(2-chlorophenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)



RN 24280-93-1 HCPLUS

CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-
isobenzofuranyl)-4-methyl-, (4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 25614-03-3 HCAPLUS


CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 37270-94-3 HCPLUS

CN Blood platelet factor 4 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 38096-31-0 HCPLUS

CN 9,10-Anthracenedione, diamino- (9CI) (CA INDEX NAME)

2 [D1-NH₂]

RN 50679-08-8 HCPLUS


CN 1-Piperidinebutanol, .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- (9CI) (CA INDEX NAME)



RN 51481-61-9 HCPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488



RN 52698-84-7 HCAPLUS

CN 1,10-Phenanthroline, 2,9-dimethyl-4,7-diphenyl-, disulfo deriv., disodium salt (9CI) (CA INDEX NAME)




$$2 \left[\text{D1-SO}_3\text{H} \right]$$

● 2 Na


RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 65899-73-2 HCAPLUS

CN 1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 70050-43-0 HCAPLUS


CN Histidine, .alpha.- (fluoromethyl)- (9CI) (CA INDEX NAME)



RN 75847-73-3 HCAPLUS

CN L-Proline, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.




RN 76547-98-3 HCAPLUS

CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 84088-42-6 HCAPLUS
CN 3-Quinolinecarboxamide,
1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-
(9CI) (CA INDEX NAME)




RN 110590-61-9 HCAPLUS
CN L-Argininamide,
L-cysteinyl-L.-alpha.-aspartyl-L-prolylglycyl-L-tyrosyl-L-
isoleucylglycyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 1-B



RN 114798-26-4 HCAPLUS


CN 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[{2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl]- (9CI) (CA INDEX NAME)



RN 126509-46-4 HCAPLUS

CN Heptanamide, N-[(1S)-1-(hydroxymethyl)-2-[(1S)-1-[(2R)-2-(hydroxymethyl)oxiranyl]carbonyl]-3-methyl-3-butenyl]amino]-2-oxoethyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 129912-34-1 HCAPLUS

RN 135911-02-3 HCAPLUS

CN 4H-Isoindol-4-one, octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-, (3aR,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 182930-58-1 HCAPLUS

CN Morpholine, 4-[3-[4-(2-chlorophenyl)-9-methyl-1H-thieno[2,3-b]thiophene-2-yl]methyl]morpholine-4-carbonitrile
Searched by John Dantzman 308-4488

f] [1,2,4]triazolo[4,3-a][1,4]diazepin-2(6H)-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



IT 51-45-6, Histamine, biological studies 11128-99-7,
 Angiotensin II 33507-63-0, Substance P 65154-06-5,
 Platelet activating factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; angiogenesis suppressors for inhibiting hair growth)
 RN 51-45-6 HCPLUS
 CN 1H-Imidazole-4-ethanamine (9CI) (CA INDEX NAME)




RN 11128-99-7 HCPLUS
 CN Angiotensin II (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 33507-63-0 HCPLUS
 CN Substance P (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH₂



PAGE 2-A



Searched by John Dantzman 308-4488

RN 65154-06-5 HCAPLUS
CN Blood platelet-activating factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 9015-82-1, Angiotensin-converting enzyme 9023-09-0,
Sulfotransferase 9024-61-7, Histidine decarboxylase
9039-06-9, Cytochrome P450 reductase 9055-65-6,
Prostaglandin synthetase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; angiogenesis suppressors for inhibiting hair growth)
RN 9015-82-1 HCAPLUS
CN Carboxypeptidase, dipeptidyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9023-09-0 HCAPLUS
CN Sulfotransferase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9024-61-7 HCAPLUS
CN Decarboxylase, histidine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9039-06-9 HCAPLUS
CN Reductase, cytochrome P 450 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9055-65-6 HCAPLUS
CN Synthase, prostaglandin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***